Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service

Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNAtm in Frontiers in Oncology


Regulatory News:

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced the publication of the results of preclinical studies comparing the efficacy and toxicity of two DNA repair inhibitors: olaparib, a PARP inhibitor, and AsiDNAtm, the Company's first-in-class DDR inhibitor, in the peer-reviewed journal, Frontiers in Oncology. In-vivo models showed that, while both DNA repair inhibitors were effective, only AsiDNAtm could delay resistance to carboplatin without increasing its toxicity.

Françoise BONO, Chief Scientific Officer of Onxeo, commented: "The results of these in-vivo studies highlighted the distinctive characteristics of our clinical stage product candidate, AsiDNAtm. Most importantly, these studies show AsiDNA'stm ability to delay resistance to carboplatin without increasing its toxicity, a critical property that has not previously been observed in anti-cancer agents, including olaparib. In addition, the studies confirmed the overall good safety profile of AsiDNAtm. These translational studies, conducted in collaboration with the research laboratory of Marie Dutreix at the Institut Curie, were instrumental in our decision to prioritize the clinical development of AsiDNAtm in combination with chemotherapy. We now look forward to the preliminary data from our ongoing DRIIV-1b Phase 1b clinical study of AsiDNAtm in combination with a reference chemotherapy (carboplatin and paclitaxel), expected in a few weeks."

The original research article, titled "Preclinical studies comparing efficacy and toxicity of DNA repair inhibitors, olaparib and AsiDNA, in treatment of carboplatin resistant tumors," is currently available on the Frontiers in Oncology website.

Upcoming events

  • November 12-13, 2019

Bryan, Garnier & Co European Healthcare Conference

Paris, France

  • November 12-15, 2019

Tides Europe 2019

Amsterdam, Holland

  • January 29-31, 2020

PARP & DDR Inhibitors Summit 2020

Boston, MA, USA

About Onxeo

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

platONtm is Onxeo's proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company's product pipeline.

AsiDNAtm, the first compound from platONtm, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNAtm, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNAtm has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNAtm by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNAtm in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

OX401 is a new drug candidate from platONtm, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

Onxeo's portfolio also includes belinostat, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US under the name Beleodaq® (belinostat IV form).

For further information, please visit www.onxeo.com.

Forward looking statements

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.7.1.4 "Risk Factors" ("Facteurs de Risque") of the 2018 registration document filed with the Autorité des marchés financiers on April 25, 2019 under number D.19-0282, which is available on the Autorité des marchés financiers website (www.amf-france.org) or on the Company's website (www.onxeo.com).


These press releases may also interest you

at 22:58
One-day mobile collections for COVID-19 testing specimens are continuing this weekend and into early next week, with the University of Mississippi Medical Center, Mississippi State Department of Health, Mississippi Emergency Management Agency and...

at 21:45
Cheeriodicals today announced the delivery of more than 200 personalized cheer-up gifts to pediatric patients at Cottage Children's Medical Center and to Veteran patients at Santa Barbara Veterans Affairs Clinic.  Cheeriodicals' gifts are made up of...

at 21:13
Kaiser Permanente has announced that it will waive all member out-of-pocket costs for inpatient and outpatient services related to the treatment of COVID-19, as of April 1, 2020. This is intended to alleviate the cost burden and stress on impacted...

at 20:58
The management of Olymel deplores the untruthful and irresponsible information that an anonymous person circulated on social networks on Friday April 3 to the effect that products from his pork processing facility in Yamachiche could transmit the...

at 20:35
As more states are ordering businesses to temporarily close and millions of residents to stay at home because of the coronavirus, Rx relief, a division of PrideStaff, is proud to partner with essential businesses and healthcare organizations, helping...

at 20:30
United Security Health and Casualty Insurance Company (United Security) recently received authorization to offer its Short Term Major Medical (STMM) plan in the state of Oklahoma. Lisa Cordero, COO, United Security began, "A Short Term Major Medical...



News published on 13 november 2019 at 12:05 and distributed by: